Latest Headlines

Latest Headlines

As Shire gears up to push Vyvanse for binge eating, critics worry about abuse

Shire is pushing full steam ahead to get the word out on binge eating disorder, the new indication it snagged for blockbuster Vyvanse last month.

UPDATED: Shire's Vyvanse brand team draws fire for aggressive binge-eating push

Shire is pushing full steam ahead to get the word out on binge eating disorder, the new indication it snagged for blockbuster Vyvanse last month. But some doctors think the Dublin drugmaker may be taking the marketing a bit too far, considering Vyvanse's abuse potential.

Shire's shopping spree continues with a $245M deal to buy PhIII-ready Meritage

Fresh from completing a $5 billion deal for NPS Pharma, Shire stopped to bag a small San Diego biotech, picking up Meritage Pharma and a Phase III-ready rare disease drug for $70 million upfront and a slate of unspecified milestones.

Shire touts R&D benefits in defense of tax model

Shire CEO Flemming Ornskov has come out fighting against vocal critics of the company's tax model. As Ornskov sees it, Shire's tax structure is fully legal, similar to the model used by around 500 companies and beneficial to patients.

Genzyme touts postmarket study of Cerdelga, the only first-line oral therapy for Gaucher disease

Rare disease specialist Genzyme talked up the results of a study published in  The Journal of the American Medical Association  concluding that the only first-line oral therapy for Gaucher disease reduced spleen size 28% compared to placebo after 9 months.

Shire and Valeant are reportedly eyeing $10B bids for Salix

Salix Pharmaceuticals, moving on from an embarrassing inventory scandal, is reportedly headed for a bidding war between two larger companies with diametric approaches to the business of developing drugs.

UPDATED: Valeant, Shire prep Salix bids

Earlier this month, rumors started swirling that Valeant was talking with its advisers about a potential bid for North Carolina's Salix Pharmaceuticals. Now, it's reportedly one step closer to making that happen--but it may not be alone.

Shire hails its best-ever pipeline with a 'busy' R&D year ahead

Shire has laid out an ambitious goal of effectively doubling its revenue in the next few years, bringing in $10 billion by 2020, and CEO Flemming Ornskov said the acquisitive biotech has a bullpen of potential therapies that will help it come through on that promise.

Shire set to grow in 2015, but don't expect a repeat of last year, it says

Shire has some hefty sales forecasts in place for 2020, when CEO Flemming Ornskov has said it'll be bringing in a $10 billion top-line haul. Now, after a monster sales vault in 2014, the company is nearly 60% there--but don't expect a repeat growth surge this year, it says.

Shire volleys with tennis star Seles to promote Vyvanse for binge eating

Shire's got the FDA go-ahead to market blockbuster ADHD med Vyvanse as a treatment for binge eating disorder (BED). It just has to make sure doctors and patients understand what BED actually is. To do that, it's signed on former tennis superstar Monica Seles, who has struggled with the condition.